Adeno-Associated Viral Vectors: Unlocking the Future Opportunities

Given the potential of gene therapies in targeting the underlying cause of a disease at cellular level, the demand for such therapies has increased considerably over the past few years.

Currently, more than 285 gene therapies are being evaluated in different phases of clinical development. Further, various gene therapy developers have raised more than USD 10 billion capital during the year 2021. With the growing interest in such therapies, the demand for novel delivery vectors has also increased. Among various gene delivery vectors available, adeno-associated viral vectors have emerged as one of the most efficient viral vectors. Till now, the USFDA has approved two adeno-associated viral vectors-based drugs, LUXTURNA® and ZOLGENSMA®.

In order to cater to the demand, close to 100 players, across the globe, have emerged for the development and manufacturing of adeno-associated viral vectors. In fact, a number of these companies also offer advanced technology platforms, enabling the processing of AAV vectors and related therapies across different scales of operation. Various industry and non-industry players are actively engaged in research and development of novel gene delivery technologies, which are safe and effective.

155+ Clinical Trials have been / are being conducted
The stakeholders have invested extensively in conducting clinical trials for evaluating the efficacy of the therapeutic candidates in the treatment of a variety of indications.

~4,300 Patent Filed / Granted in the Domain
Examples of leading industry stakeholders, in terms of most patent applications filed include Genzyme, Voyager Therapeutics, REGENXBIO, Baxalta and Spark Therapeutics.

200+ Partnerships and Collaborations signed in the Domain
The growing partnerships and collaborations signed between different stakeholders is indicative of the significant demand of vectors and related therapies from the past few years.

As projected by Roots Analysis, oncological disorders therapeutic area will have majority share in the adeno-associated viral vector market. As projected by Roots Analysis, the overall market of AAV vector manufacturers market is expected to expand in the coming years.

For additional details, please visit https://www.rootsanalysis.com/....blog/adeno-associate or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

😂😂😂

Traumi infantili che avevo rimosso e che riaffiorano grazie a #barbascurax. Mi pare corretto che anche voi tutti li riviviate.

Per innevare artificialmente 1 ettaro di #piste da #sci si producono dai 700 ai 1.300 kg di #co2, ma gli studi di settore sono ancora pochi e danno risultati variabili. A questa CO2 va poi anche aggiunta quella prodotta dai mezzi battipista, dei quali non esistono varianti elettriche.
#curiosiclubbez #ecologia #cambiamentoclimatico #virale #surriscaldamentoglobale #neve #natura #montagna #inverno #ambiente #clubbez

Da giorni, sul social di #zucchina continuo a vedere post e articoli riguardo la lettera al direttore di #gente dalla madre preoccupata perché i figli leggono troppi #manga e lei non sa come fare per riportarli sulla retta via e a letture più consone. Per chi non lo sapesse, la risposta del direttore è un arrendevole "Bhò, fammi sapere se lo scopri da sola che ho lo stesso problema." (perdonatemi la parafrasi). Ora, ciò che mi lascia stupito e perplesso di tutta la vicenda, non è la chiusura mentale e retrograda che traspare dallo scambio, non è l'alzata di lance e scudi immediatamente sollevata in rete a difesa del medium manga tanto amato, ma il fatto che nessuno abbia tratto quella che sono convinto è l'ovvia conclusione: siamo di fronte ad una lettera e una risposta palesemente costruite ad hoc, per generare polemica e rendere virale un hashtag, né più né meno.
"Ma così contribuisci pure tu a rendere virale la cosa" potrete obiettare.
VERO, ma dato che fino ad ora non ho visto nessuno far notare questa cosa, mi è sembrato doveroso farlo.
Tu che ne pensi William J?

Modular Construction – Retrofitting Conventional Buildings

Shifting construction away from traditional sites and into factories could dramatically change the way we build.

What is Modular Construction?
Modular Construction is a process in which different components known as Modules are constructed in a controlled factory setting and later assembled on the desired site as per the requirement of the user. In general, 60% to 90% of the work is completed offsite while the rest on the location where the facility is needed. The factory-made, standard modules are accustomed with walls, doors, ceilings, frames, and windows. Additionally, the modules can be integrated with more specific components, such as air handling units, fan filter units, air showers along with the lighting and plumbing facility intended for pharmaceutical use. It is worth mentioning, majority of the modular facilities built are GMP certified ensuring required quality standards have been met while construction.

Types of Modular Construction
Modular Construction can be broadly categorized into two categories, namely permanent and relocatable. Permanent modular builds mean the facilities are constructed to be used at the same location wherein it has been assembled. In other words, the building is similar to conventionally constructed infrastructure except the fact it has been built off-site. Whereas relocatable or temporary builds are designed in such a way that they can be transported to different locations applicable for rental as well as purchase purposes.

Need for Modular Facilities
Conventional construction has never shown to surpass 80% mark owing to factors including logistical delays, type of material used, method of construction adopted and shortage of manpower eventually hampering the productivity. Whereas prefabricated approaches have reported to increase productivity by more than 100%. Modular construction acts as a sustainable method empowering today’s construction sector.

The Modular Construction Process
In the first phase, a description of the building that is to be constructed is created through discussion between the customer and modular building manufacturer followed by review of the engineering department to evaluate whether the proposed design meets all the applicable building codes. Then, granting of building permit is required in most jurisdictions for constructing new structures, or performing major renovations. Post getting approvals, site wherein the structure needs to be delivered is prepared. Further, the plant is fabricated at a offsite location, transported and installed at the client’s location.

Modular Construction in Pharmaceutical Industry
The concept of modular construction has been used in other industries for a long time; however, over the past two to three decades, it has only gained significant attention within the pharmaceutical industry.
Moreover, there is immense pressure on drug manufacturers to market novel drugs as soon as possible, before patent expiry. Increased pressure to expedite time to market, coupled with the need to decrease operating costs and increase manufacturing efficiencies, have amplified the value of smaller production facilities, which are more efficient and flexible. The modular construction market developments have made modular facilities more attractive to drug manufacturers today, as these facilities can quickly switch between multiple drugs, enabling formulation and packaging in multiple formats, such as solid, liquid, semi-solid and parenteral dosage forms. With this new set of requirements, drug manufacturers have started showing evident interest in modular facilities and using modularity in design approaches.

For additional details, please visit https://www.rootsanalysis.com/....blog/modular-constru

You may also be interested in the following titles:
1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

Ecco 😅😅😅

Il politically correct 😅😅😅

Per ricordarvi che oggi esce la terza stagione di #themandalorian, eccovi il riassuntone della seconda stagione ad opera de #ilridoppiatore

L’ultimo #antenato comune tra #animali e #funghi è avvenuto molto più tardi rispetto all’ultimo antenato comune tra #piante e funghi. Geneticamente siamo più simili ai funghi che alle piante, ma non solo solo, anche i funghi sono geneticamente più simili a noi che alle piante. Hai mai avuto l'impressione che la consistenza dei funghi che mangi fosse più simile a quella della #carne che a quella della #verdura? Ora sai perché.
#curiosiclubbez #evoluzione #virale #natura #biodiversità #vita #clubbez